Literature DB >> 27825637

RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.

Rafael Rosell1, Niki Karachaliou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27825637     DOI： 10.1016/S1470-2045(16)30557-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

Review 2.  Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.

Authors:  Wagner Ricardo Montor; Andrei Ronaldo Oliveira Silva Escartin Salas; Fabiana Henriques Machado de Melo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

3.  An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer.

Authors:  Brian C Haynes; Richard A Blidner; Robyn D Cardwell; Robert Zeigler; Shobha Gokul; Julie R Thibert; Liangjing Chen; Junya Fujimoto; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Gary J Latham
Journal:  Transl Oncol       Date:  2019-04-12       Impact factor: 4.243

4.  Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.

Authors:  Frédéric Dugay; Francisco Llamas-Gutierrez; Marjory Gournay; Sarah Medane; François Mazet; Dan Christian Chiforeanu; Emmanuelle Becker; Régine Lamy; Hervé Léna; Nathalie Rioux-Leclercq; Marc-Antoine Belaud-Rotureau; Florian Cabillic
Journal:  Oncotarget       Date:  2017-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.